ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015
Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 1: Compositions and Features.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Biodistribution of Tc-99m-Labeled Solid Lipid Nanoparticles and Evaluation of Their Possibility as a Radiopharmaceutical.Molecules (Basel, Switzerland) · 2026Article
- A Narrative Review of Biomarkers and Imaging in the Diagnosis of Acute Aortic Syndrome.Diagnostics (Basel, Switzerland) · 2025Review
- The Use of Medicinal Plant-Derived Metallic Nanoparticles in Theranostics.Pharmaceutics · 2022Review
- X-ray excited luminescence spectroscopy and imaging with NaGdFRSC advances · 2021Article
- Laser activatable perfluorocarbon bubbles for imaging and therapy through enhanced absorption from coupled silica coated gold nanoparticles.RSC advances · 2021Article
- PET imaging of macrophages in cardiovascular diseases.American journal of translational research · 2020Review
- Cardiovascular optoacoustics: From mice to men - A review.Photoacoustics · 2019Review
- Molecular Imaging of the Heart.Comprehensive Physiology · 2019Review
- Wulff in a cage gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging.Nanoscale · 2018Article
- Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.ACS nano · 2018Review
- Molecular Imaging in Drug Discovery and Development.Circulation. Cardiovascular imaging · 2018Review
- Computational Analysis on Down-Regulated Images of Macrophage Scavenger Receptor.Pharmaceutical research · 2017Article
- Vascular targeting of nanoparticles for molecular imaging of diseased endothelium.Advanced drug delivery reviews · 2017Review
- Tunable and noncytotoxic PET/SPECT-MRI multimodality imaging probes using colloidally stable ligand-free superparamagnetic iron oxide nanoparticles.International journal of nanomedicine · 2017Article
- Design and Modular Construction of a Polymeric Nanoparticle for Targeted Atherosclerosis Positron Emission Tomography Imaging: A Story of 25% (64)Cu-CANF-Comb.Pharmaceutical research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Imaging agents made from nanoparticles are functionally versatile and have unique properties that may translate to clinical utility in several key cardiovascular imaging niches. Nanoparticles exhibit size-based circulation, biodistribution, and elimination properties different from those of small molecules and microparticles. In addition, nanoparticles provide versatile platforms that can be engineered to create both multimodal and multifunctional imaging agents with tunable properties. With these features, nanoparticulate imaging agents can facilitate fusion of high-sensitivity and high-resolution imaging modalities and selectively bind tissues for targeted molecular imaging and therapeutic delivery. Despite their intriguing attributes, nanoparticulate imaging agents have thus far achieved only limited clinical use. The reasons for this restricted advancement include an evolving scope of applications, the simplicity and effectiveness of existing small-molecule agents, pharmacokinetic limitations, safety concerns, and a complex regulatory environment. This review describes general features of nanoparticulate imaging agents and therapeutics and discusses challenges associated with clinical translation. A second, related review to appear in a subsequent issue of JNM highlights nuclear-based nanoparticulate probes in preclinical cardiovascular imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.